

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Knowlton Orsula V</u> (Last) (First) (Middle) 228 STRAWBRIDGE DRIVE SUITE 100 (Street) MOORESTOWN NJ 08057 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Tabula Rasa HealthCare, Inc. [TRHC]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">President</p>
	3. Date of Earliest Transaction (Month/Day/Year) 01/17/2019	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/17/2019		S ⁽¹⁾⁽⁶⁾		2,924	D	\$63.54 ⁽²⁾	779,437	D	
Common Stock	01/17/2019		S ⁽¹⁾⁽⁷⁾		3,396	D	\$64.71 ⁽³⁾	776,041	D	
Common Stock	01/17/2019		S ⁽¹⁾⁽⁸⁾		400	D	\$65.7 ⁽⁴⁾	775,641	D	
Common Stock	01/17/2019		S ⁽¹⁾⁽⁹⁾		1,080	D	\$66.52 ⁽⁵⁾	774,561	D	
Common Stock	01/17/2019		S ⁽¹⁾⁽¹⁰⁾		200	D	\$67.63	774,361	D	
Common Stock								840,129	I	Held by spouse.
Common Stock								10,000	I	Held by trust for children.
Common Stock								10,000	I	Held by trust for children.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Explanation of Responses:

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2018.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$63.12 to \$64.10, inclusive. The reporting person undertakes to provide to Tabula Rasa HealthCare, Inc., any security holder of Tabula Rasa HealthCare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$64.31 to \$65.15, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$65.31 to \$66.12, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$66.37 to \$66.92, inclusive.

6. The sales aggregated in Row 1 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by Dr. Calvin H. Knowlton on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and Dr. Calvin H. Knowlton has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.

7. The sales aggregated in Row 2 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by Dr. Calvin H. Knowlton on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and Dr. Calvin H. Knowlton has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.

8. The sales aggregated in Row 3 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by Dr. Calvin H. Knowlton on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and Dr. Calvin H. Knowlton has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.

9. The sales aggregated in Row 4 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by Dr. Calvin H. Knowlton on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and Dr. Calvin H. Knowlton has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.

10. The sale in Row 5 of Table I is not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by Dr. Calvin H. Knowlton on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and Dr. Calvin H. Knowlton has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.

/s/ Brian W. Adams, by Power 01/23/2019
of Attorney

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.